Company attributes
Other attributes
Neuralstem, Inc. is a company that is interested in providing research into stem cells and creating human neural stem cell technologies. The company was founded by Richard Garr in 1996, in Rockville, Maryland, United States.
The company is interested in developing their treatments to help diseases of the central nervous system such as ALS and Parkinsons, as well as traumatic spinal cord injury. Their treatment is in an FDA-approved Phase I safety clinical trial for Lou Gehrig's disease. The company is also interested in treating ischemic spastic paraplegia, chronic stroke, and Huntington's disease.
The company is interested in finding new treatments and biopharmaceuticals for neurological disorders, and then commercializing those products. The company has completed Phase II of Clinical studies in China for the treatment of Ischemic strokes. Seneca is focused on finding and acquiring new assets that will improve technologies for therapeutics. They provide global licensing of novel monoclonal antibodies for treating auto-immune diseases.
